Prevalence and outcomes of primary hyperparathyroidism in sarcoidosis patients: a large-scale retrospective cohort study
Authors' conclusion
PHPT is prevalent, profoundly under-evaluated, and undertreated in sarcoidosis.
Study context
- Population
- US adults with ICD-10 sarcoidosis (D86) and ≥1 serum calcium measurement, TriNetX U.S. Collaborative Network
- Participants
- 117,395 adults
- Outcome
- iPTH assessment rate; biochemical and coded PHPT prevalence; PTX utilization and outcomes; all-cause mortality
Methodological detailsfederated EHR data (TriNetX U.S. Collaborative Network)
- Federated EHR data (TriNetX U.S. Collaborative Network)
Main finding
As reported in the abstract
Hypercalcemia, iPTH evaluation and PHPT prevalence
- Hypercalcemia (n=36,790)
- 31.3%
- Hypercalcemia with iPTH measured
- 30.5%
- Biochemical primary hyperparathyroidism (PHPT) (n=3,493)
- 3.0%
- Biochemical PHPT without ICD-10 code (n=2,633)
- 75.4%
- PTX in coded PHPT (n=315)
- 36.6%
- Biochemical cure after PTX
- 74.6%
Observational data: associations, not effects.
Further findings
All-cause mortality
| HR (CI) | P value | ||
|---|---|---|---|
| Hypercalcemia | 1.33 (1.29–1.38) | P < 0.001 | |
| Coded PHPT | 1.50 (1.40–1.60) | P < 0.001 | |
| No PTX | 4.2 (2.7–6.4) | P < 0.001 | |
| 0.10.31310Hazard ratio (log scale) |
Original publication
Prevalence and outcomes of primary hyperparathyroidism in sarcoidosis patients: a large-scale retrospective cohort study. J Clin Endocrinol Metab. Published 28 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →